CAS Insight

molecules of the month

Pfizer CoV-2 MPro Inhibitor

oral pan-coronavirus antiviral, rev. covalent

Ph. III candidate for COVID-19 (300 mg BID)

from SARS-CoV-1 inhibitor (WO2005113580)

paxlovid (PF-07321332)

Pfizer Worldwide Research

paxlovid structure PF-07321332 drug hunter molecules of the year
3 mins read

Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which received emergency use authorization from the FDA for Covid treatment at the end of 2021. Clinical data showed Paxlovid reducing Covid hospitalization and death by 89%. It was nominated for November’s cover by Mike Koehler, Christian Kuttruff, and Callie Bryan. “Paxlovid sets a speed record in development that may never be broken!” said Mike Koehler. Their Science paper describing the development came out in the same month that their clinical trial was ended early due to strong efficacy. “I looked up some other recent molecules with rapid development times, and the standouts are the CFTR modulators, which were in trials for only about three years (but took a…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: